多药耐药相关蛋白2在乳腺癌组织中的表达及与预后关系_临床医学论文.docVIP

多药耐药相关蛋白2在乳腺癌组织中的表达及与预后关系_临床医学论文 多药耐药相关蛋白2在乳腺癌组织中的表达及与预后关系_临床医学论文 作者：　王树滨，孙宇萍，刘雅洁，陈亦欣，徐敏，陈伟，隋广杰，杨纯正 【关键词】 乳腺肿瘤；基因；MDR；多药耐药相关蛋白 　　［摘要］ 目的：研究多药耐药相关蛋白2(Multidrug resistanceassociated protein 2，MRP2)在乳腺癌组织中的表达，评估其在乳腺癌预后中的作用。方法：采用免疫组织化学方法（Immuno Histo Chemistry，IHC）检测47例手术切除的乳腺癌组织中MRP2的表达，并分析其与临床、病理特征的关系及对预后的影响。结果：MRP2在乳腺癌组织中的阳性表达率为85.1%(40/47)，其中高表达者25例(53.2%)；MRP2表达与月经状况、肿瘤大小、腋淋巴结转移、组织分级和激素受体状况均无关（Pgt;0.05）；KaplanMeier生存分析结果表明MRP2表达与无病生存期和总生存期均无关(Pgt;0.05)；COX多因素分析显示只有肿瘤大小和腋淋巴结转移和无病生存期和总生存期明显相关(0.05)。结论：MRP2在乳腺癌组织中具有一定的表达水平，但与乳腺癌患者预后无关。 　　［关键词］ 乳腺肿瘤；基因；MDR；多药耐药相关蛋白2；预后 　　The Prognostic Significance of Multidrug Resistanceassociated Protein 2Expression in Primary Breast Carcinoma 　　Abstract：Objective Intrinsic and/or acquired resistance was the major obstacle to overcome in the treatment of patients with breast cancer.The aim of the present study was to investigate the relationship between the expression of multidrug resistanceassociated protein 2 (MRP2) with the clinicpathologic characteristics and the prognosis in primary breast cancer patients.Methods Expression of MRP2 in 47 breast cancer patients was determined by immunohistochemistry on formalinfixed，paraffinembedded tumor section.Results MRP2 expression was observed in 40 of 47(85.1%).No relation can be established between expression of MRP2 and other clinicopathologic parameters.KaplanMeier analyses revealed that MRP2 expression didnt associated with diseasefree survival (DFS) or overall survival (OS) (Pgt;0.05).In multivariate Cox regression analysis，tumor size and lymph node metastasis was independent prognostic factors for survival (0.05).Conclusion Our results suggested that MRP2 is frequently expression in primary breast cancer，but MRP2 is not a poor prognostic factor in patients with breast cancer. 　　Key words：Breast carcinoma;Gene;MDR;Multidrug resistanceassociated protein 2(MRP2);Prognosis 　　对化学治疗（化疗）耐药是导致乳腺癌治疗失败的主要原因之一，国内外研究表明，肿瘤耐药涉及细胞内药物浓度降低、药物靶分子改变、代谢解毒、DNA损伤修复功能增强等多种机制，与多种耐药相关基因有关，由MRP2介导的耐药是除P糖蛋白(Pg